Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
KYMR

KYMR - Kymera Therapeutics, Inc. Stock Price, Fair Value and News

$79.06+1.56 (+2.01%)
Market Closed

13/100

KYMR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

13/100

KYMR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KYMR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KYMR Price Action

Last 7 days

-5.3%

Last 30 days

-3.9%

Last 90 days

-11.8%

Trailing 12 Months

136.4%

KYMR RSI Chart

KYMR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KYMR Valuation

Market Cap

6.5B

Price/Earnings (Trailing)

-20.73

Price/Sales (Trailing)

164.62

Price/Free Cashflow

-27.54

KYMR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KYMR Fundamentals

KYMR Revenue

Revenue (TTM)

39.2M

Rev. Growth (Yr)

-61.18%

Rev. Growth (Qtr)

3.85%

KYMR Earnings

Earnings (TTM)

-311.4M

Earnings Growth (Yr)

-22.94%

Earnings Growth (Qtr)

-5.85%

KYMR Profitability

Return on Equity

-19.71%

Return on Assets

-17.86%

Free Cashflow Yield

-3.63%

KYMR Investor Care

Shares Dilution (1Y)

25.71%

Diluted EPS (TTM)

-3.69

KYMR Alerts

  • 6 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202558.9M44.7M43.7M39.2M
202479.4M88.5M87.6M47.1M
202346.7M51.7M46.8M78.6M
202263.8M56.7M46.0M46.8M
202149.3M64.5M70.3M72.8M
202010.7M18.5M26.3M34.0M
20190002.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Kymera Therapeutics, Inc.

KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEkymeratx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES181

Kymera Therapeutics, Inc. Frequently Asked Questions

KYMR is the stock ticker symbol of Kymera Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Kymera Therapeutics, Inc. is 6.45 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, KYMR's PE ratio (Price to Earnings) is -20.73 and Price to Sales (PS) ratio is 164.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KYMR PE ratio will change depending on the future growth rate expectations of investors.